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Abstract
Objectives—Platelet activation and aggregation play an important role in the pathogenesis of
cardiovascular disease. We examined the association of a single nucleotide polymorphism (SNP)
in the GPIIIa platelet glycoprotein (Leu33Pro) with carotid artery plaque morphology and with
expression of platelet markers using data from the Atherosclerosis Risk in Communities (ARIC)
Carotid MRI study.
Methods—The study sample consisted of 1,202 Caucasian members of the ARIC study cohort
recruited in 2004-2005 to participate in the Carotid MRI Substudy under stratified sampling based
on maximum carotid artery wall thickness. The Leu33Pro polymorphism was identified as SNP
rs5918 in the ITGB3 gene. Plaque visualization was accomplished with contrast enhanced MRI
examination of the thickest segment of the carotid artery. Expression of platelet markers was
measured using fasting whole blood flow cytometry.
Results—This cross-sectional analysis based on age and gender adjusted weighted linear
regression models suggests that those homozygous for the Leu33Pro risk allele (C) have decreased
mean and minimum fibrous cap thickness. We did not observe differences in plaque lipid volume
or maximum carotid artery wall thickness across SNP rs5918 genotypes. Carriers of the Leu33Pro
polymorphism, as compared to major allele homozygotes, had greater percent of platelets
expressing P-selectin, a platelet glycoprotein indicating activation status. Prevalent coronary heart
disease did not affect estimates of fibrous cap thickness or of platelet activation.
Conclusion—Our results suggest that individuals with Leu33Pro polymorphism of the GPIIIa
glycoprotein may be predisposed to increased risk of atherosclerotic plaque rupture.
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Introduction
The term ”vulnerable plaque” [1] refers to an atherosclerotic lesion in which a lipid-rich
core, infiltrated by macrophages, is contained within a thin fibrous cap. Based on
examination of autopsy specimens Kolodgie et al.[2] suggested that vulnerability of the
plaque to rupture is defined primarily by the thinness of the fibrous cap and proposed a term
“thin cap fibroatheroma” that identifies morphologically distinct lesions which vary in the
volume and area of the lipid core, but which share the characteristically thin fibrous cap. The
focus of this study is the association of a polymorphism in the platelet integrin GPIIb/IIIa
with atherosclerotic plaque characteristics.
The GPIIb/IIIa integrin, the most abundant platelet–specific glycoprotein [3], exists as a
heterodimer of two subunits: the αIIb chain and the β3 chain. This integrin functions as a
receptor for ligands such as fibrinogen, von Willebrand factor and vitronectin [4-6] and is
critical for the binding of platelets to the extracellular matrix of the blood vessel wall and to
each other, thus facilitating platelet aggregation. Platelet aggregation is an essential step in
formation of the thrombus [7] and in subsequent blood vessel wall remodeling [8]. In
quiescent platelets, the αIIbβ3 glycoprotein is in a conformation which does not allow for
ligand binding. Activation of platelets induces a conformational change in the cytoplasmic
portion of the glycoprotein and subsequently, in the process of inside-out signaling [9], in
the extracellular portion, exposing the extracellular Arg-Gly-Asp (RGD) ligand binding
tripeptide [10]. In the GPIIIa protein (β3 chain), the RGD binding sequence is located in the
same area as the most common platelet polymorphism, known as the Leu33Pro
polymorphism or the PlA1/PlA2 polymorphism. This genetic variation has been examined for
association with clinical coronary artery disease endpoints, but the results are not conclusive
[11,12].
Evaluation of the association of the Leu33Pro polymorphism with intermediate phenotypes
characterizing atherosclerotic lesions is possible only in studies that are designed to examine
atherosclerotic plaque morphology. The Carotid MRI component of the Atherosclerosis Risk
in Communities (ARIC) Study is one of the few studies that provide that information. We
therefore used data from the ARIC Carotid MRI study to examine the association of the
Leu33Pro single nucleotide polymorphism (SNP) in the ITGB3 gene coding for the GPIIIa
platelet glycoprotein with MRI measurements defining carotid artery plaque morphology
and with expression of platelet markers.
Methods
Study participants
The ARIC Study includes a population based cohort of men and women aged 45-64 at
baseline (1987-1989) selected as a probability sample from four communities in the United
States [13]. Participants of the ARIC Carotid MRI study [14] were selected from the
population of ARIC Study members alive in 2004, such that 1200 were recruited based on
their high (field center-specific cutpoints) carotid intima media thickness (IMT) levels
determined at the last ARIC study visit (1993-1996) and 800 participants were recruited
from the remaining cohort population through stratified random sampling. In total, 4306
ARIC cohort members were invited to participate in the ARIC Carotid MRI study. Of those,
1403 refused participation, 837 were ineligible for an MRI examination, leaving 2066 as the
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final number of Carotid MRI study participants. Individuals were ineligible for the study if
they had any of the following: implanted metallic devices; carotid revascularization on
either side for the low IMT group or on the side selected for imaging on the high IMT
group; weight greater than 320 pounds; difficulties in understanding questions; or
difficulties in completing the informed consent form. We excluded from the present study
individuals with missing MRI scans (n=127), those for whom all attributes could not be
ascertained (n=169), individuals who underwent chemotherapy or steroid treatment four
weeks or less prior to the study visit (n= 75), those with missing information for all platelet
variables (n=118), those missing information on plaque variables (n=360), and those
missing genotype information (n=109). We further restricted the study to whites, as the total
number of black study participants with the minor risk allele was too low for meaningful
analyses (n=2). The final study sample consisted of 1,202 ARIC study participants.
Institutional Review Boards of each study center approved the study protocols and all study
participants provided informed consent.
Genotyping
TagSNPs within selected candidate genes were derived using the Haploview Program based
on two sources of SNPs: the Caucasian (CEU) and Yoruban (YRI) population from the
International HapMap project. The data were analyzed by the ARIC study DNA laboratory
in a race specific manner using the gene definitions provided by the HapMap database. The
dbSNP database was used as the primary source for the data on each gene. Genotyping was
performed using a custom designed iSelect Infinium BeadChip with 7,600 bead types.
Concordance of duplicated samples for all SNPs was 99.998% .
The Leu33Pro polymorphism was identified as SNP rs5918 in the ITGB3 gene located on
chromosome 17. Minor allele frequency for this SNP in the ARIC Carotid MRI population
was 0.15 among whites and 0.09 among blacks. The corresponding minor allele frequencies
reported in the HapMap project are 0.14 for the CEU population and 0.13 for the YRI
population.
MRI acquisition
A contrast-enhanced MRI exam was performed using a standard protocol as previously
reported [15]. Exams were acquired on 1.5 T MRI scanners (Excite platform, GE Medical
Systems; Symphony Maestro, Siemens Medical Solutions) using 4-element phased array
carotid coils (Machnet, The Netherlands). A 3D time-of-flight MR angiogram (MRA) was
acquired to include both extracranial carotid bifurcations. Detailed high-resolution black
blood MRI (BBMRI) images were then acquired through the carotid with the higher
maximum wall thickness based on a prior ultrasound, unless the contralateral carotid wall
appeared thicker on the MRA to the technologist, in which case the contralateral carotid was
chosen for detailed imaging. BBMRI imaging was performed using a 2D electrocardiogram
(ECG)-gated double inversion recovery fast spin-echo sequence with the inversion time set
to suppress the signal of luminal blood (repetition time/echo time, 1 RR/5 msec; acquired in-
plane resolution, 0.51×0.58×2 mm3). Images were acquired before and 5 minutes after the
injection of gadodiamide (Omniscan, GE Healthcare), 0.1mmol/kg. For this study, all MRI
variables were derived from the postcontrast series that included 16 slices (3.2cm
longitudinal coverage).
MRI Image Analysis
The postcontrast BBMRI images were analyzed by seven trained readers using
semiautomated software (VesselMASS, Leiden University Medical Center). Details of the
analysis were previously described [15]. Readers drew contours to delineate the outer wall,
lumen, and lipid core. The fibrous cap contour was automatically generated based on the
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lumen and lipid core contours. Only 8 of the 16 slices were analyzed (1.6 cm segment),
selected as those centered on the slice depicting the thickest wall. Each exam received an
image quality and protocol adherence score and failed exams were not analyzed.
The analysis software divided vessel walls into 12 radial segments and fibrous caps into
radial segments at 15° increments for each slice. Mean thickness values were generated for
the vessel wall and area measurements were generated for the lipid core. Volumetric data
were computed by integrating area measurements over the eight contiguous analyzed slices.
Mean cap thickness was defined as the mean thickness of all caps segments at two adjacent
slices with the largest core, and minimum cap thickness was defined as the mean of the two
minimum cap segment thicknesses at these two slices with the largest core. Reliability
estimates for these derived MRI variables were previously reported [15].
Flow cytometry
Flow cytometry was performed using fasting whole blood samples which were stored in
Cyto-Chex® BCT vacutainer tubes (Streck, Omaha, NE) containing EDTA and a blood cell
stabilizer. The tubes were shipped at room temperature in temperature-stabilizing packages
overnight to a central flow-cytometry laboratory. Details of the flow cytometry protocols
and reproducibility of used methods have been described elsewhere [16]. We examined
percent cells positive for selected platelet surface glycoproteins and for median fluorescence
intensity associated with those markers. Antigen-negative controls were used to set the
threshold between positive and negative cell populations. The coefficient of variation was
less than 10% for most analytes. A validation study conducted among 55 study participants,
indicated high repeatability (R>0.60) for the measurement of the CD62P antigen.
Statistical analysis
We used weighted linear regression analysis to determine age-, gender- and study center-
adjusted means of selected characteristics of the study participants as well as plaque and
platelet characteristics. Analyses were weighted by the inverse of the sampling fractions
used in the design of the ARIC Carotid MRI study. All analyses were cross-sectional and
were based on a recessive model. Analyses of atherosclerotic plaque characteristics were
limited to individuals with maximum segmental wall thickness equal to or greater than 1.5
mm in order to exlude those cases with cores too small to be detected by the resolution
constraints of the MRI scanner, and analyses of the fibrous cap thickness were limited to
participants with maximum segmental wall thickness equal to or greater than 1.5 mm and
with a present lipid core. Additionally, we explored a vector of plaque vulnerability using
the method of principal components analysis [17] based on the following variables
associated with plaque morphology: mean cap thickness, minimum cap thickness, maximum
lipid core volume, and maximum segmental wall thickness. Weighted linear regression
analysis was performed on the relevant principal components to examine their relationship
to the genotypes as described above.
Analyses were performed using STATA 10.0 (STATACORP LP, College Station, Texas)
and SUDAAN (RTI International, Research Triangle Park, Durham, NC)
Results
The minor allele (C) frequency of SNP rs5918 of the ITGB3 gene was 15% among ARIC
whites, similar to the 14% reported among the HapMap CEU population. The genotype
distribution conformed to Hardy-Weinberg equilibrium.
We did not observe many differences in the characteristics of study participants according to
the SNP rs5918 genotype (Table 1). The percent of individuals with self-reported use of
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anti-hyperlipidemic medication was higher among individuals homozygous for the major
allele as compared to heterozygotes and those homozygous for the minor allele. Levels of
glucose, mean total cholesterol, mean HDL-cholesterol, and mean LDL cholesterol were
similar among major allele homozygotes and heterozygotes, but differed significantly for
minor allele homozygotes.
Figure 1 shows atherosclerotic plaque characteristics stratified by ITGB3 rs5918 genotype.
In comparison with heterozygotes and with individuals homozygous for the major allele,
individuals homozygous for the minor allele had a smaller total wall volume (p=0.04) and
smaller maximum segmental wall thickness (p=0.01). The total lipid core volume and the
maximum lipid core area was the highest among those homozygous for the minor allele,
although the differences were not statistically significant. The percent of individuals with
visible lipid core presence in any of the eight MRI slices was lower among individuals
homozygous for the minor allele in comparison with heterozygotes and with those
homozygous for the major allele. For both measures of the fibrous cap thickness (mean and
minimum), individuals homozygous for SNP rs5918 minor allele exhibited values that were
significantly lower than those observed for either heterozygotes or for major allele
homozygotes. Initial analysis was performed with adjustment for age, gender, maximum
segmental wall thickness, and ARIC study center. No significant attenuation of estimates
was observed in adjustment for smoking (current, former, or never), prevalent coronary
heart disease, diabetes, levels of total and non-HDL cholesterol and use of
antihyperlipidemic medication and aspirin.
Principal components analysis of mean cap thickness, minimum cap thickness, maximum
lipid core volume, and maximum segmental wall thickness identified two principal
components, one associated with a thick fibrous cap, thick wall, and large volume of the
lipid core; the other was positively associated with fibrous cap thickness and to a lesser
degree negatively associated with lipid core volume and maximum segmental wall thickness
(data not shown). In regression analysis adjusted for age and gender, we found the second
principal component to be inversely associated with the presence of both minor alleles of
SNP rs5918 (mean difference: −1.3737, 95% CI: −1.9223, −0.8248), while regression
analyses performed with the first principal component were null (data not shown).
We observed a gradient in levels of platelet activation marker P-selectin across the SNP
rs5918 genotype (Figure 2). Individuals homozygous for the major allele (T) had 25.9 (SE
0.5) percent of platelets expressing P-selectin. That percent increased among heterozygotes
to 30.7 (SE 1.0) and it was 38.1 (SE 3.2) among minor allele (C) homozygotes. The
differences in levels of P-selectin between the genotype groups were statistically significant
(p<0.05).
Discussion
This cross-sectional analysis based on age- and gender-adjusted weighted linear regression
models suggests that the Leu33Pro polymorphism may be associated with changes in the
structure of atherosclerotic plaques. Specifically, individuals homozygous for the risk allele
(C) of SNP rs5918 in the ITGB3 gene may have decreased mean and minimum thickness of
the atherosclerotic plaque fibrous cap and increased total lipid core volume, as compared to
heterozygotes and major allele homozygotes. We did not observe significant differences in
maximum carotid artery wall thickness across SNP rs5918 genotypes. Carriers of the
Leu33Pro polymorphism, as compared to major allele homozygotes, had greater percent of
platelets expressing P-selectin, a platelet glycoprotein that indicates platelet activation
status. Prevalent coronary heart disease did not affect estimates of fibrous cap thickness or
levels of platelet markers.
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The GPIIb/IIIa glycoprotein plays an essential role in the final common pathway leading to
platelet aggregation and formation of the thrombus plug [18]. Receptors found at the
extracellular portion of this transmembrane integrin protein serve to bind activated platelets
to ligands such as fibrinogen and von Willebrand factor [19] thus facilitating platelet-platelet
binding and adhesion of platelets to the exposed extracellular matrix of the vascular wall.
Glycoprotein IIb/IIIa antagonists have been used clinically in prevention of subsequent
thrombotic events among patients with acute coronary syndromes and those undergoing
percutaneous intervention [20,21].
Platelet glycoproteins are highly polymorphic, with the Leu33Pro polymorphism of the
GPIIIa glycoprotein ITGB3 gene as the most common platelet polymorphism. The
association of the Leu33Pro polymorphism with the incidence of coronary heart disease first
reported by Marian et al. [22] has been examined in numerous other studies with mixed
results [12]. Meta-analysis results suggest a slight increase in coronary heart disease risk
among individuals with the Leu33Pro polymorphism; however, the range of reported effect
estimates is very wide. We sought to examine the association of this polymorphism with
intermediate phenotypes which ultimately may lead to clinically manifest coronary heart
disease, namely plaque morphology and platelet activation. Our observation that the
Leu33Pro polymorphism is associated with decreased fibrous cap thickness of the
atherosclerotic plaque confirms reports of a positive association of this genetic variant with
increased risk of thrombosis and increased extent of coronary artery disease [23,24].
We observed a gradient in levels of platelet surface glycoprotein P-selectin across genotypes
of the rs5918 SNP. P-selectin, stored in the cytosolic Wabe-Pallade bodies of the platelet, is
released upon platelet activation and expressed on the platelet surface. Thus, an increase in
percent of platelets expressing P-selectin is considered a marker of increased platelet
activation. While in vitro studies of the association of the Leu33Pro polymorphism with
platelet activation are not conclusive [25-27], it is possible that the conflicting reports may
reflect modification of the effect of the genotype on platelet aggregability by fibrinogen and
perhaps other ligands.
The majority of the studies examining the association of the Leu33Pro variant with clinical
endpoints have combined the risk allele homozygotes with heterozygotes in the exposure
category. However, our results suggest that the effect of the Leu33Pro polymorphism on
plaque characteristics is observed only for risk allele homozygotes. Inclusion of
heterozygotes in the exposure category would dilute the effect estimates for intermediate
phenotypes and, by extension, for clinical endpoints. This dilution may be potentiated by the
significantly greater heterozygote genotype frequency, as compared to that of risk allele
homozygotes. Several studies [28-30] have reported wide ethnic variation in the distribution
of the Leu33Pro polymorphism, with whites exhibiting the largest mean minor allele
frequency. Analyses of the association of this polymorphism with clinical outcomes in
populations of mixed race and ethnicity may dilute the effect estimate and bias results
towards the null. Analyses presented here were performed only among whites.
Our study had several limitations. Most importantly, the number of individuals with the
minor allele of SNP rs5918 of the ITGB3 gene was very small. Our small sample size was
partly dictated by the fact that the MRI resolution limited our analysis to the largest
observed plaques. We further constrained the analysis of plaque morphology to include only
individuals with thick arterial walls. It is therefore possible that our observations were due to
chance. In a sensitivity analysis we examined the association of two distinct chromosome 17
SNPs (rs8069732 and rs7214096) which are in linkage disequilibrium with SNP rs5918 with
the selected plaque and platelet outcomes. They both showed associations similar to those
observed with SNP rs 5918; however, the minor allele frequency for those SNPs was
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similarly less than 15%. Low minor allele frequency and small sample size disallowed
analyses in the black participants of the ARIC Carotid MRI study. Despite the resulting
small sample size, our effect estimates were stable and consistent with clinical observations.
We were not able to perform a replication study for this analysis because no other study
exists that provides similar data. To our knowledge, the Multi-Ethnic Study of
Atherosclerosis (MESA) is to date the only other population-based study of carotid artery
plaque morphology by magnetic resonance imaging with extant data. However, the number
of completed MRIs in MESA in individuals with plaques thick enough to analyze is only
214, and thus would provide very limited power for replication that is already compromised
by the low minor allele frequency of the rs5918 SNP.
The major strength of this study is that it was performed using validated data from an
established cohort study. Our data show internal consistency, such that low thickness of the
fibrous cap among the minor allele homozygotes corresponded with a relatively greater lipid
core area and volume in that group, as compared to the heterozygotes and the major allele
homozygotes, suggesting the presence of lipid-rich thin cap fibroatheromas.
In conclusion, our observations suggest that the Leu33Pro polymorphism is associated with
increased level of platelet activation as well as decreased fibrous cap thickness. Although
those two manifestations of a prothrombotic state may be causally related, it is not possible
to assess causality in this cross-sectional study. The results however, suggest that individuals
with the Leu33Pro polymorphism of the GPIIIa glycoprotein may be predisposed to
increased risk of atherosclerotic plaque rupture due to both a thinning fibrous cap and as a
result of a sustained pro-inflammatory state.
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Association of the SNP rs5918 polymorphism of the platelet GPIIIa glycoprotein with
atherosclerotic plaque characteristics. Adjustment for age, gender, study center, and
smoking.
The ARIC Carotid MRI Study.
* Analysis limited to whites with maximum wall thickness ≥1.5mm
**Analysis limited to whites with maximum wall thickness ≥1.5mm with additional
adjustment for maximum wall thickness
*φAnalysis limited to whites with maximum wall thickness ≥1.5mm and with presence of
lipid core.
A. maximum wall thickness; B. total wall volume; C. percent of plaques with lipid core; D.
total lipid core volume; E. maximum lipid core area; F. fibrous cap thickness
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Association of SNP rs5918 of the GPIIIa platelet glycoprotein with platelet activation. Age
and gender adjusted percent (SE). Whites only. p-for trend <0.01. The ARIC Carotid MRI
study
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Table 1
Weighted means (SE) or percent of study participant characteristics according to SNP rs5918 genotype: The








Age (years) 70.7 (0.2) 70.6 (0.2) 70.7 (0.4)
Gender (% male) 44.5 46.7 49.4
BMI (kg/m2) 28.4 (0.2) 27.9 (0.4) 28.2 (0.9)
Glucose (mg/dL) 106.5 (1.0) 107.9 (1.6) 104.7 (3.0)
Total cholesterol (mg/dl) 190.7 (1.6) 201.1 (3.5) 179.4 (7.7)*
HDL-cholesterol (mg/dL) 49.6 (0.6) 50.6 (1.2) 47.2 (2.4)
LDL-cholesterol (mg/DL) 110.1 (1.5) 118.2 (3.0) 101.3 (7.5)*
Triglycerides (mg/dL) 190.7 (1.6) 201.1 (3.5) 179.4 (7.7)
Diabetes (%) 19.8 22.1 20.2
Hypertension (%) 59.0 64.0 56.8
Prevalent CHD (%) 11.6 6.8 11.1
Use of anticoagulants (%) 4.6 2.1 0*
Use of anti-hyperlipidemic medication (%) 47.8 37.6 35.6
Use of antiplatelet medication (%) 3.2 1.4 2.4
Use of aspirin (%) 54.5 47.5 55.9
Current smokers (%) 7.6 6.8 8.9
*
Levels of total cholesterol and LDL-cholesterol were significantly different (p<0.05) between individuals homozygous for the minor allele (CC)
and heterozygotes. Use of anticoagulants among those homozygous for the minor allele was significantly different (p<0.05) from anticoagulant use
in both the heterozygotes and in the major allele homozygotes. No other statistically significant differences in the distribution of population
characteristics were observed.
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